https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27851 Thu 17 Mar 2022 14:39:27 AEDT ]]> Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15288 Sat 24 Mar 2018 08:21:53 AEDT ]]> Parents' experiences of postmortem tumor donation for high-grade gliomas: Benefits and suggested improvements https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48481 Mon 20 Mar 2023 09:59:40 AEDT ]]> Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49686 Fri 02 Jun 2023 12:33:56 AEST ]]>